Progesterone receptors appear in granulosa cells of preovulatory follicles after the midcycle gonadotropin surge, suggesting important local actions of progesterone during ovulation in primates. Steroid reduction and replacement during the gonadotropin surge in macaques was used to evaluate the role of progesterone in the ovulatory process. Animals received gonadotropins to induce development of multiple preovulatory follicles, followed by human chorionic gonadotropin (hCG) administration (day 0) to promote oocyte (nuclear) maturation, ovulation, and follicular luteinization. On days 0-2, animals received no further treatment; a steroid synthesis inhibitor, trilostane (TRL); TRL + R5020; or TRL + dihydrotestosterone propionate (DHT). On day 3, ovulation was confirmed by counting ovulation sites and collecting oviductal oocytes. The meiotic status of oviductal and remaining follicular oocytes was evaluated. Peak serum estradiol levels, the total number of large follicles, and baseline serum progesterone levels at the time of hCG administration were similar in all animals. Ovulation sites and oviductal oocytes were routinely observed in controls. Ovulation was abolished in TRL. Progestin, but not androgen, replacement restored ovulation. Relative to controls, progesterone production was impaired for the first 6 days post-hCG in TRL, TRL + R5020, and TRL + DHT. Thereafter, progesterone remained low in TRL but recovered to control levels with progestin and androgen replacement. Similar percentages of mature (metaphase II) oocytes were collected among groups. Thus, steroid reduction during the gonadotropin surge inhibited ovulation and luteinization, but not reinitiation of oocyte meiotic maturation, in the primate follicle. The data are consistent with a local receptor-mediated role for progesterone in the ovulatory process.
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A hallmark of reproductive cycles in female mammals is the process of ovulation. A triad of well-coordinated events occurs locally within the ovarian follicle during the periovulatory interval. First, the follicle-enclosed oocyte undergoes both nuclear and cytoplasmic maturation to render it capable of fertilization. Second, the mature, preovulatory follicle ruptures-i.e., ovulates-to release the oocyte. Third, luteinization of the steroidogenic somatic cells of the follicle, known as theca and granulosa cells, results in morphological differentiation to form the corpus luteum. The ovulatory process is initiated by the surge of pituitary gonadotropins, mainly luteinizing hormone (LH) , that occurs at midcycle (1) . Other factors produced within the follicle during the periovulatory period, such as metabolites of arachidonic acid (2) , peptides (3) , and steroids (4), likely play a role in LH-induced ovulation, at least in rodent models. Understanding the ovulatory process is obligatory for development of therapies to alleviate infertility due to ovulatory dysfunction, such as the luteinizing unruptured follicle syndrome (5) in women, as well as alternative methods for controlling fertility by preventing ovulation (6) .
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Progesterone receptors have been detected by immunocytochemistry in the ovaries of several species (7) (8) (9) , including the monkey (10) and human (11, 12) , suggesting local actions for progesterone in ovarian function. The nuclei of theca cells in developing preovulatory as well as periovulatory follicles in primates expressed progesterone receptors (10, 11) . However, nuclear progesterone receptors were absent from granulosa cells until after the midcycle LH surge (10, 11) . Recent studies in laboratory animals (7, 13, 14) , pigs (15) , as well as nonhuman primates (16, 17) confirmed that expression of progesterone receptors and its mRNA in granulosa cells is positively regulated by either an endogenous or an exogenous gonadotropin surge. Furthermore, progesterone receptor mRNA and protein are detectable in the primate corpus luteum during the menstrual cycle (10, 11, 17, 18) . These studies support the hypothesis of progesterone action via classical receptormediated pathways in the luteinizing follicle and corpus luteum of the primate ovary.
In rodents, progesterone has been shown to be a mediator of the ovulatory process. Ablation of progesterone synthesis (19, 20) or action with anti-progestin antiserum (21) or the antiprogestin RU 486 (22) (23) (24) during the gonadotropin surge completely inhibited ovulation-i.e., follicle rupture-which was reestablished upon concomitant administration of progesterone. Antiprogestins also prevented LH-induced luteinization of rat granulosa cells in vitro (14) . With respect to the participation of progesterone in other periovulatory events such as oocyte maturation, few studies have been performed in rodents. In primates, the local role of progesterone in ovulation and other periovulatory events is unknown.
Inhibition of progesterone synthesis during the gonadotropin surge of stimulated cycles in macaques was used to test the hypothesis that progesterone acts locally in the primate follicle at midcycle to promote periovulatory events. The use of this nonhuman primate model offers two advantages over using animals during a normal menstrual cycle. First, the length of the follicular phase can be controlled to precisely time the midcycle gonadotropin surge with exogenous human chorionic gonadotropin (hCG) and multiple oocytes can be retrieved. Second, this model allows alterations in ovarian steroidogenesis while obviating steroid feedback effects on pituitary gonadotropin secretion. Thus, the consequences of steroid inhibition reflect local actions on periovulatory follicles and their enclosed oocytes. Oocyte maturation, ovulation, and luteinization were evaluated following progesterone reduction and replacement with a synthetic progestin and a nonmetabolizable androgen. Primate Research Center has been described (25) . Adult female rhesus monkeys with regular 28-day menstrual cycles were checked daily for menses, and with its onset a superovulation protocol known to reliably produce multiple follicular development and ovulation was initiated (26 (27) .
MATERIALS AND METHODS
Blood samples were obtained daily from unanesthetized animals by saphenous venipuncture between 0800 and 0900 h, beginning on the 1st day of follicular stimulation and continuing until the next menses. Serum concentrations of estradiol, progesterone, R5020, and DHT were determined by RIA in the Hormone Assay Core Laboratory (25, 27) . In animals receiving TRL ± steroids, serum samples collected the morning prior to hCG/TRL administration and for 7 days thereafter underwent chromatography to separate progesterone from pregnenolone prior to RIA as described (28) .
Evaluation of Oocyte Maturation, in Vitro Fertilization, and Follicular Ovulation. At 72 h after the ovulatory hCG bolus, anesthetized animals underwent paramedian pelvic laparotomy for quantitation of ovulation sites and retrieval of oocytes by retrograde oviductal lavage (26) and/or follicle aspiration (25) . Oocytes were isolated and counted, and their nuclear maturity was evaluated following brief exposure to hyaluronidase to remove the cumulus cells (25) . Oocytes were classified as prophase I (intact germinal vesicle), metaphase I (MI; no germinal vesicle, no polar body), metaphase II (MIT; one polar body), and atretic (presence of fragmentation or vacuoles in the ooplasm). Semen from rhesus males was collected by penile electroejaculation and washed, and motility and density were determined, and semen was incubated and activated as described (25) analyzed by the Kruskal-Wallis test, followed by the MannWhitney U test for comparisons between treatments. The proportion of follicles of the total cohort at a given diameter as well as the proportion of oocytes at various stages of nuclear maturity were compared between groups using Fisher's exact test or x2 analysis. Differences were considered significant at P < 0.05.
RESULTS
The follicular response to human gonadotropin stimulation in the control group and the groups that subsequently received TRL alone or with progestin or androgen replacement was similar as indicated by serum levels of estradiol and the number of preovulatory follicles recruited. In all groups, serum estradiol increased progressively, reaching peak levels on the morning prior to administration of the hCG ovulatory stimulus [control, 6963 ± 3836 pg/ml (mean ± SEM); TRL, 3228 ± 1563 pg/ml; TRL + R5020, 4535 ± 563; TRL + DHT, 2602 ± 750]. Similarly, the total number of large follicles per animal was not different among controls (15 ± 0), and macaques to be treated with TRL (13 ± 1), TRL + R5020 (15 ± 3), and TRL + DHT (20 ± 2). Likewise, the distribution of follicle sizes, ranging from 3 to 6 mm in diameter and expressed as percentage of the total cohort, did not differ between groups (data not shown). Progesterone levels throughout the follicular phase and on the morning prior to the hCG injection were at baseline (<0.5 ng/ml) in all groups.
The ovulatory status of control animals and those receiving TRL alone or with steroid replacement during the periovulatory interval is summarized in Table 1 . All control animals ovulated, evidenced by multiple ovulatory stigmata and oocytes obtained in the oviductal flush in two of four animals. In contrast, TRL-treated animals failed to ovulate as shown by complete absence of ovulation sites ( Fig. 1) and oocytes in the oviductal lavage. Ovulation was reestablished in animals receiving progestin (R5020) replacement during TRL administration, with oocytes recovered from the oviducts of two of three animals. In contrast, concomitant administration of androgen (DHT) with TRL resulted in the appearance of only three ovulatory stigmata in one animal, and no oocytes were recovered following oviductal lavage.
Of the total number of oocytes collected per animal by either the combination of oviductal lavage and follicle aspiration (controls and TRL + R5020) or aspiration alone (TRL and TRL + DHT), the percentage of mature (MII) oocytes did not differ among groups (Table 2 ). While the fertilization rate for MII oocytes inseminated in vitro was high in control animals, fewer (P < 0.05) oocytes from only two of four TRL-treated animals underwent in vitro fertilization. Although relatively fewer oocytes were available for insemination in the TRL + R5020 group, none of them were fertilized. In contrast, in vitro fertilization was achieved at a greater (P < 0.05), albeit variable, rate in three of three animals receiving TRL + DHT relative to TRL alone; however, this fertilization rate remained lower (P < 0.05) than that of controls.
Circulating levels of R5020 in the TRL + R5020 group were nondetectable on the morning prior to the hCG/R5020 injection (day 0) but increased to 17.0 ± 7.2 ng/ml (mean ± SEM) by 1300 h that afternoon. Thereafter, levels declined to 5.5 ± 2.8 ng/ml on day 3 post-hCG (oviduct lavage) and to 1.6 ± 1.0 ng/ml on day 4. In the TRL + DHT group, serum levels of DHT were at baseline (0.08 ± 0.01 ng/ml) on the morning of day 0 and increased to 7.5 + 1.3 ng/ml that afternoon. Levels of DHT remained constant through day 3 post-hCG (8.6 + 0.7 ng/ml) but then declined to 2.8 ± 0.4 ng/ml by day 6. Serum progesterone levels during the periovulatory period and subsequent luteal phase are depicted in Fig. 2 . In controls, progesterone increased within 24 h of hCG to levels of 7.0 + 1.8 ng/ml. Peak levels of 49.3 ± 23.5 ng/ml, indicative of the presence of multiple corpora lutea, were attained on days 4-6 post-hCG, which then declined to baseline prior to menses. In marked contrast to controls, progesterone levels remained at baseline (P < 0.05), as expected, in all macaques during TRL treatment (days 1-2 post-hCG). Levels also remained suppressed (P < 0.05) in TRL-treated animals on days 3-8 post-hCG relative to controls, although three of four animals exhibited some circulating progesterone (5.2 ± 2.1 ng/ml) by day 7 post-hCG, which declined thereafter. In TRL + R5020, all three animals had progesterone levels above baseline (3.7 ± 0.9) within 4 days post-hCG that were still decreased (P < 0.05) relative to controls. By day 6 post-hCG progesterone levels were variable but not different from those of controls; one animal in the TRL + R5020 group exhibited serum progesterone values on days 6-7 post-hCG of 22.1 ng/ml. In TRL + DHT, one animal never achieved progesterone levels above 0.4 ng/ml throughout the luteal phase, while the other two animals exhibited recovery of progesterone production (8-10 ng/ml), albeit less than controls, by day 7 post-hCG. Progesterone levels in these TRL + DHT animals were then similar to controls from day 8 post-hCG until menses.
Animals in all groups exhibited evidence of timely menses. There was no difference in the length of the luteal phase among the control (13 ± 1 days; mean ± SEM), TRL (12 ± 1), TRL + R5020 (13 ± 1), and TRL + DHT (13 + 1) groups.
DISCUSSION
This study examines a role for progesterone in periovulatory events during the menstrual cycle in primates. The presence of progesterone receptor mRNA and protein in the granulosa cells of the primate follicle after the LH surge and in the developing corpus luteum (10, 11; 16-18) suggests that progesterone may function as a local regulator in periovulatory and luteal events. In the present study, progesterone synthesis by luteinizing follicles was ablated by using a competitive inhibitor of 303-hydroxysteroid dehydrogenase activity, TRL (29) . This steroidal compound does not bind to progesterone receptors (30) and rapidly reduces progesterone to levels incapable of supporting early pregnancy in macaques (29) . TRL was effective in suppressing hCG-induced progesterone production by periovulatory follicles, as demonstrated by baseline (<0.5 ng/ml) levels during the first 3 days post-hCG. Since luteinizing granulosa cells are the source of progesterone, the low serum progesterone levels likely reflect low intrafollicular concentrations as well. However, direct measurement of follicular fluid progesterone levels was not attempted due to blood contamination that routinely occurs during aspiration of macaque follicles (28) .
The suppression of serum progesterone by TRL during the periovulatory period was associated with complete inhibition of ovulation in gonadotropin-stimulated rhesus monkeys. Re- establishment of ovulation in TRL-treated animals with the addition of the progestin agonist R5020 but not with the nonmetabolizable androgen DHT adds further support to the concept of a local role for progesterone in ovulatory events. Our data support the contention that continuous administration of the antiprogestin RU 486 to nonpregnant women during the normal menstrual cycle prevents ovulation in a dose-dependent manner not only by suppression of the midcycle LH surge but by direct effects on the ovary as well (31) .
Our data are also consistent with evidence that progesterone is a local regulator of the ovulatory process in rodents (19) (20) (21) , acting through a receptor-mediated (22, 23) autocrine/ paracrine pathway on the periovulatory follicle. While the mechanism(s) is unknown, recent studies suggest that progesterone regulates proteolytic enzyme activity (24, 32) thought to be involved in the digestion and rupture of the follicle wall. Bona fide evidence for ovulation requires both follicular rupture and release of oocytes as observed within the oviduct and/or their absence from within the follicle subsequent to the time of estimated ovulation. In our study, follicular rupture and oocytes in the oviductal lavage were observed only in control animals and in those that received progestin but not androgen replacement during TRL treatment. Although the number of oocytes recovered by lavage does not correlate with the number of ovulatory stigmata present on the ovaries, this latter observation may be related to (i) the difficulty in retrograde flushing of macaque oviducts; (ii) a change in the rate of gamete transport in ovarian stimulation cycles or in the presence of R5020; or (iii) degeneration of oocytes within the oviduct by the collection time chosen to maximize the incidence of ovulatory stigmata (72 h post-hCG). Failure of the follicle to rupture with entrapment of the oocyte and subsequent luteinization of the surrounding granulosa cells (e.g., "luteinized unruptured follicle syndrome") has been documented as a cause of infertility in women (33) . While oocytes were retained in macaques that received TRL or TRL + DHT based on follicle aspiration, histological analyses will be necessary to confirm whether these follicles underwent luteinization.
Inhibition of progesterone synthesis by TRL in periovulatory macaque follicles did not prevent reinitiation of oocyte meiotic maturation, and meiosis was not enhanced by progestin replacement. Therefore, the reinitiation of oocyte nuclear maturation triggered by the midcycle gonadotropin surge does not require increasing levels of progesterone prior to follicular rupture. Likewise, in another study (28) , chronic (10-day) exposure to TRL throughout stimulation of multiple follicular development in gonadotropin-treated macaques did not inhibit oocyte nuclear maturation. In addition, hamster oocytes matured normally when exposed to TRL in vitro (34) , while mouse oocyte maturation was unaffected by antiprogestin treatment (35) . It is also noteworthy that androgen replacement during steroid reduction in the periovulatory period did not alter oocyte nuclear maturation relative to controls. In contrast, a high intrafollicular androgen environment is correlated with detrimental effects on oocyte nuclear maturation in women (36) and macaques (27) . Androgens other than DHT or greater intrafollicular androgen levels than were achieved in the present study may be more potent inhibitors of oocyte meiosis in primates.
The fertilization rate of MII oocytes inseminated in vitro was markedly impaired in animals receiving periovulatory TRL compared to control animals. In the present study, oocytes were retrieved later (72 h post-hCG) than is customary during macaque (27 h) or human (34 h) in vitro fertilization cycles, which may influence fertilization rates. Nevertheless, the fertilization level achieved by oocytes collected from both follicular aspirates and oviductal lavage in control animals was relatively high. Fertilization was similarly impaired following administration of TRL throughout the follicular phase of gonadotropin-stimulated in vitro fertilization cycles in macaques (28) . Although a direct toxic effect on oocyte function cannot be ruled out, these studies suggest that inhibition of 3f3-hydroxysteroid dehydrogenase reduces oocyte fertilizability. In the present study, oocyte fertilization was not restored with R5020 replacement; although this dose restored ovulation, it is possible that progestin requirements differ for promoting oocyte fertilization. Alternatively, a classical, receptor-mediated role for progesterone may not be involved in the maturational events required for oocyte fertilization (37) . Surprisingly, DHT restored a variable albeit greater level of fertilization compared to TRL and TRL + R5020. While a high androgen/estradiol ratio during the preovulatory interval was associated with decreased fertilization in macaques (27) , the levels of androgen achieved during DHT replacement in the present study were relatively lower. Possibly, DHT confers some protective effect in the presence of TRL or has undefined promotional functions on oocyte fertilizability in primates. Lastly, intrafollicular elevations of substrates for 3f3-hydroxysteroid dehydrogenase-i.e., pregnenolone or dehydroepiandrosterone-during TRL exposure may impair oocyte fertilization (see ref. 28 ).
Synthesis of progesterone was completely suppressed during the periovulatory period in animals undergoing midcycle 313-hydroxysteroid dehydrogenase inhibition. Unexpectedly, this suppression continued in the subsequent luteal phase, with marked reduction in circulating progesterone compared to controls. Residual effects of TRL in the early luteal phase might explain some of the inhibition, but the magnitude and duration of effect suggest that periovulatory progesterone may act in an autocrine/paracrine fashion to promote luteal development and function as originally proposed by Rothchild (38) . This hypothesis is supported by the ability of R5020 administered during the periovulatory period to restore appreciable progesterone production by midluteal phase. It is possible that the discrepancy between the restoration of ovulation and the delay in recovery of progesterone synthesis in the TRL + R5020 group is due to an inadequate dose or suboptimal interval of R5020 exposure. This effect may not be specific to progestin since androgen replacement was also associated with increased progesterone production in some animals. Immunocytochemical evidence for androgen receptors in the macaque (39) and human (40) corpus luteum support a function for androgens in luteal development and/or function. Furthermore, the duration of progesterone inhibition during the gonadotropin surge may have differential effects on subsequent luteal development. When TRL administration was ended on the day of hCG injection in gonadotropinstimulated macaques (28) , progesterone was profoundly suppressed for only 72 h post-hCG, with restoration to levels about half those of controls by midluteal phase compared to the more marked reduction reported in the present study. The mechanisms whereby progesterone stimulates its own production in primates, in concert with LH, are not fully understood but could include the promotion of angiogenesis, low density lipoprotein-cholesterol uptake, 3,3-hydroxysteroid dehydrogenase activity, or other factors necessary for luteal function.
In summary, the present study supports the concept of a local, receptor-mediated role for progesterone in ovulation, oocyte fertilizability, and corpus luteum development but not oocyte meiotic maturation in primates. An important challenge is to identify the cellular sites of action and the underlying mechanisms regulated by progesterone during the periovulatory period. Understanding the role of progesterone during the ovulatory process will aid in the development of novel contraceptives based on inhibition of ovulation and subsequent luteal development. Furthermore, elucidation of progesterone-mediated events during ovulation in the nonhuman primate model will be valuable for development of new strategies for alleviating infertility in women due to luteinized unruptured follicle syndrome, aberrant oocyte fertilization, and luteal phase defects associated with insufficient progesterone production.
